10-KPeriod: FY2012

AMGEN INC Annual Report, Year Ended Dec 31, 2012

Filed February 27, 2013For Securities:AMGN

Summary

Amgen Inc. reported robust revenue growth of 11% for the fiscal year 2012, reaching $17.265 billion. This growth was primarily driven by strong performance across its key products, including Neulasta®, Enbrel®, XGEVA®, and Prolia®, which saw significant increases in sales. The company also continued its commitment to returning capital to shareholders through a substantial stock repurchase program and an increased quarterly dividend. Amgen made significant progress in its R&D pipeline, advancing several promising candidates, such as AMG 145, brodalumab, romosozumab, and rilotumumab, into Phase 3 clinical trials. However, the company faces challenges including upcoming patent expirations for key products like NEUPOGEN® and Aranesp®, which are expected to increase competition from biosimilars. Additionally, evolving reimbursement landscapes and ongoing regulatory scrutiny, particularly concerning Enbrel® and its erythropoiesis-stimulating agents (ESAs), present potential headwinds.

Financial Highlights

55 data points
Beta

Revenue

$17.27B

81.5% Gross Margin

Net Income

$4.34B

25.2% Net Margin

EPS (Diluted)

$5.52

Total Assets

$54.30B

Cash & Equivalents

$3.26B

Free Cash Flow

$5.19B

Financial Statements
Beta
Revenue$17.27B
Cost of Revenue$3.20B
Gross Profit$14.07B
SG&A Expenses$4.81B
Operating Expenses$11.69B
Operating Income$5.58B
Interest Expense$1.05B
Net Income$4.34B
EPS (Basic)$5.61
EPS (Diluted)$5.52
Shares Outstanding (Basic)775.00M
Shares Outstanding (Diluted)787.00M

Key Highlights

  • 1Total revenues increased by 11% to $17.265 billion in 2012, driven by strong product sales.
  • 2Key products like Neulasta® (up 4%), Enbrel® (up 14%), XGEVA® (up over 100%), and Prolia® (up over 100%) showed significant sales growth.
  • 3Amgen advanced several product candidates (AMG 145, brodalumab, romosozumab, rilotumumab) into Phase 3 clinical trials, bolstering its future pipeline.
  • 4The company returned significant capital to shareholders, repurchasing $4.7 billion in stock and increasing its quarterly dividend by 31%.
  • 5Patent expirations for NEUPOGEN® (December 2013) and Aranesp® are anticipated, leading to increased competition from biosimilars, particularly in the US.
  • 6Sales of ESAs (Aranesp® and EPOGEN®) continued to decline due to regulatory label changes and reimbursement pressures.
  • 7Amgen acquired Mustafa Nevzat Pharmaceuticals and Micromet Inc. in 2012, expanding its reach and capabilities.

Frequently Asked Questions

Amgen demonstrated strong financial performance in 2012, with total revenues growing 11% to $17.265 billion. Net income also increased by 18% to $4.345 billion, and diluted earnings per share rose by 37% to $5.52, reflecting robust sales across its product portfolio and effective cost management.

Revenue growth was primarily driven by strong sales of Neulasta®, Enbrel®, XGEVA®, and Prolia®. Key challenges include the upcoming expiration of patents for NEUPOGEN® and Aranesp®, which will increase competition from biosimilars, and continued regulatory scrutiny and reimbursement pressures impacting the sales of ESAs.

Amgen is actively advancing its product pipeline, with several key candidates moving into Phase 3 clinical trials, including AMG 145 for hyperlipidemia, brodalumab for psoriasis, romosozumab for osteoporosis, and rilotumumab for gastric cancer. The company also made strategic acquisitions in 2012, including Mustafa Nevzat Pharmaceuticals and Micromet Inc., to enhance its commercial presence and R&D capabilities.

Amgen returned capital to shareholders through an active stock repurchase program, buying back $4.7 billion worth of its common stock in 2012. Additionally, the company increased its quarterly cash dividend by 31% in 2012, signaling confidence in its ongoing financial strength and future prospects.